Ultragenyx Pharmaceutical's GAAP loss for 9M 2021 was $331.567 million, having doubled from $162.555 million in the previous year. Revenue increased by 49.3% to $268.017 million compared to $179.488 million a year earlier.
Ultragenyx Pharmaceutical's GAAP loss for 9M 2021 was $331.567 million, having doubled from $162.555 million in the previous year. Revenue increased by 49.3% to $268.017 million compared to $179.488 million a year earlier. 
ir.ultragenyx.com
English (US) 